Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tongue and teeth hyperpigmentation in etoposide, prednisolone, vincristine, and cyclophosphamide regimen in the treatment of cutaneous lymphoma.
Indian J Pharmacol
January 2024
Department of Pharmacy Practice, B. V. V. S. Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote, Karnataka, India.
Cutaneous extranodal non-Hodgkin lymphoma is a rare cancer and chemotherapeutic agents like etoposide, vincristine and cyclophosphamide are the drug of choice, which rarely cause hyperpigmentation in skin and nails. However, herein we present a case of hyperpigmentation that was seen in tongue and even in teeth. The hyperpigmentation of the tongue and teeth occurred shortly after the initiation of chemotherapy.
View Article and Find Full Text PDFMucocutaneous Findings in Hematolymphoid Neoplasms: An Observational Study.
Indian Dermatol Online J
August 2023
Department of Medical Oncology Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Background: Cutaneous manifestations of hematological neoplasms can be divided into three broad categories - direct infiltration, paraneoplastic conditions, and those due to the treatment of hematological cancers.
Objectives: To study the frequency and patterns of mucocutaneous manifestations in patients with hematolymphoid neoplasms and those due to chemotherapy.
Materials And Methods: This was an observational study done with 172 patients.
Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature.
Int J Dermatol
July 2020
Skin Research Center, Department of Dermatology, School of Medicine, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran.
Background: Breast cancer patients may experience an increased chance of survival with adjuvant chemotherapy. However dermatologic adverse effects can cause major discomfort due to physical or cosmetic problems. This study aims to describe dermatologic complications in breast cancer patients during chemotherapy.
View Article and Find Full Text PDFToxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
J Oncol Pharm Pract
December 2020
Ohio State Global One Health Initiative, Office of International Affairs, The Ohio State University, Addis Ababa, Ethiopia.
Background: Management of patients with breast cancer undergoing chemotherapy is complicated by a very high rate of adverse drug reactions which is even more challenging in developing countries like Ethiopia where the toxicity profile of chemotherapy is lacking. The present study aimed at evaluating the toxicity profile of Doxorubicin-Cyclophosphamide (AC) and Doxorubicin-Cyclophosphamide→Paclitaxel (AC→T) regimens among 146 patients with breast cancer in Ethiopia.
Methods: This prospective cohort study, with the median of six months' follow-up, was conducted from January 1 to September 30, 2017 GC at the only nationwide oncology center, Tikur Anbessa Specialized Hospital (TASH), Addis Ababa, Ethiopia.
Cutaneous drug Reactions: Chemotherapy-induced hyperpigmentation.
Eur J Dermatol
December 2017
Department of Dermatology. Hospital General Universitario Gregorio Marañon, Madrid, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!